GlassScriptPhysician profile
Michael S Elliott
NPI 1770581803
$5,683.61
in general payments reported to CMS, 2019-2025
38 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $1,033 · 2021: $1,268 · 2022: $390 · 2023: $340 · 2024: $646 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $968.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $726.75 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $621.07 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $527.04 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $492.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $425.08 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $289.07 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.44 | 2019-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $184.42 | 2023-2025 | Gemtesa |
| Shire North American Group INC | $145.50 | 2019 | |
| Abbvie INC. | $145.39 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $105.10 | 2019-2025 | |
| Amgen INC. | $70.32 | 2019-2024 | Repatha, Otezla |
| Sanofi Pasteur INC. | $69.65 | 2019-2025 | |
| Abbott Laboratories | $67.13 | 2021-2024 | Freestyle Libre 3 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $63.05 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $49.13 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.82 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $38.50 | 2019-2020 | |
| Exact Sciences Corporation | $37.28 | 2024-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $34.82 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $32.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.36 | 2020 | |
| Currax Pharmaceuticals LLC | $25.33 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $24.40 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.80 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.78 | 2025 | Evkeeza |
| Ultragenyx Pharmaceutical INC. | $16.76 | 2022 | |
| Melinta Therapeutics, LLC | $16.57 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.30 | 2019 | |
| Amarin Pharma, INC. | $14.57 | 2019 | |
| Allergan, INC. | $13.89 | 2020 | |
| Dexcom, INC. | $13.75 | 2022 | |
| Astellas Pharma US INC | $13.70 | 2019 | |
| Vyera Pharmaceuticals, LLC | $13.67 | 2021 | |
| Almatica Pharma LLC | $13.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.99 | 2019 | |
| Eisai INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.